| Identification | Back Directory | [Name]
6-[N-(7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methanesulfonamido]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide | [CAS]
1423007-82-2 | [Synonyms]
GSK-175
GSK-175A)
GSK-2878175
GSK-2878175
(GSK2878175
3-Benzofurancarboxamide, 6-[(7-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)(methylsulfonyl)amino]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-
6-[N-(7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methanesulfonamido]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide | [Molecular Formula]
C27H23BClFN2O6S | [MDL Number]
MFCD32069543 | [MOL File]
1423007-82-2.mol | [Molecular Weight]
568.81 |
| Hazard Information | Back Directory | [Description]
GSK-2878175 is a NS5B inhibitor potentially for the treatment of HCV infection | [Uses]
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons[1]. | [References]
[1] Chong PY, et al. Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. J Med Chem. 2019;62(7):3254-3267. DOI:10.1021/acs.jmedchem.8b01719 |
|
|